Indium-111 bleomycin complex for radiochemotherapy of head and neck cancer — dosimetric and biokinetic aspects
Identifieur interne : 000046 ( Main/Exploration ); précédent : 000045; suivant : 000047Indium-111 bleomycin complex for radiochemotherapy of head and neck cancer — dosimetric and biokinetic aspects
Auteurs : RBID : ISTEX:259_1996_Article_BF00834524.pdfEnglish descriptors
- KwdEn :
Abstract
Bleomycin (BLM) is used for the treatment of head and neck cancer. In order to improve the effectiveness of this chemotherapeutic drug, BLM was combined with indium-111. A complex of these agents (111In-BLMC), formed at low pH, was injected intravenously into ten head and neck cancer patients in escalating activities of 75, 175 and 375 MBq. The internally delivered dose to the tumours varied from 0.20 to 2.73 mGy at 75 MBq, from 0.33 to 2.51 mGy at 175 MBq, and from 0.87 to 31.3 mGy at the 375 MBq activity level. Uptake of radioactivity was 0.45±0.24×10−3% ID/g in primary tumours and 0.52±0.20×l0−3% ID/g in metastases (at 48 h). Tumour volumes varied from 0.51 to 49.0 cm3. The radioactivity half-lives in the tumours were 30±7 h. The activity distribution and penetration into tumour tissue were not affected by increasing the injected activity. There was a positive correlation between BLMC uptake and Ki-67/Mib activity as well as number of mitoses in tumour tissue. These data indicate that111In-BLMC has potential as a radiochemotherapeutic agent in head and neck cancer and that adjuvant Auger-electron therapy is possible using114m-In-labelled BLMC.
DOI: 10.1007/BF00834524
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title>Indium-111 bleomycin complex for radiochemotherapy of head and neck cancer — dosimetric and biokinetic aspects</title><author><name>Kalevi J. A. Kairemo</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Chemistry, University Central Hospital of Helsinki, Finland</mods:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Clinical Chemistry, University Central Hospital of Helsinki</wicri:regionArea><wicri:noRegion>University Central Hospital of Helsinki</wicri:noRegion></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Oncology, University Central Hospital of Helsinki, Finland</mods:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Oncology, University Central Hospital of Helsinki</wicri:regionArea><wicri:noRegion>University Central Hospital of Helsinki</wicri:noRegion></affiliation></author><author><name>Hans A. Ramsay</name><affiliation wicri:level="1"><mods:affiliation>Department of Otorhinolaryngology, University Central Hospital of Helsinki, Finland</mods:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Otorhinolaryngology, University Central Hospital of Helsinki</wicri:regionArea><wicri:noRegion>University Central Hospital of Helsinki</wicri:noRegion></affiliation></author><author><name>Magnus Tagesson</name><affiliation wicri:level="1"><mods:affiliation>Department of Radiation Physics, University of Lund, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Radiation Physics, University of Lund</wicri:regionArea><wicri:noRegion>University of Lund</wicri:noRegion></affiliation></author><author><name>Antti P. Jekunen</name><affiliation wicri:level="1"><mods:affiliation>Department of Oncology, University Central Hospital of Helsinki, Finland</mods:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Oncology, University Central Hospital of Helsinki</wicri:regionArea><wicri:noRegion>University Central Hospital of Helsinki</wicri:noRegion></affiliation></author><author><name>Timo K. Paavonen</name><affiliation wicri:level="1"><mods:affiliation>Department of Pathology, University of Helsinki, Finland</mods:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Pathology, University of Helsinki</wicri:regionArea><wicri:noRegion>University of Helsinki</wicri:noRegion></affiliation></author><author><name>Hilkka A. Jääskelä-Saari</name><affiliation wicri:level="1"><mods:affiliation>Department of Otorhinolaryngology, University Central Hospital of Helsinki, Finland</mods:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Otorhinolaryngology, University Central Hospital of Helsinki</wicri:regionArea><wicri:noRegion>University Central Hospital of Helsinki</wicri:noRegion></affiliation></author><author><name>Kristian Liewendahl</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Chemistry, University Central Hospital of Helsinki, Finland</mods:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Clinical Chemistry, University Central Hospital of Helsinki</wicri:regionArea><wicri:noRegion>University Central Hospital of Helsinki</wicri:noRegion></affiliation></author><author><name>Kaj Ljunggren</name><affiliation wicri:level="1"><mods:affiliation>Department of Radiation Physics, University of Lund, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Radiation Physics, University of Lund</wicri:regionArea><wicri:noRegion>University of Lund</wicri:noRegion></affiliation></author><author><name>Sauli Savolainen</name><affiliation wicri:level="1"><mods:affiliation>Department of Physics, University of Helsinki, Finland</mods:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Physics, University of Helsinki</wicri:regionArea><wicri:noRegion>University of Helsinki</wicri:noRegion></affiliation></author><author><name>Sven-Erik Strand</name><affiliation wicri:level="1"><mods:affiliation>Department of Radiation Physics, University of Lund, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Radiation Physics, University of Lund</wicri:regionArea><wicri:noRegion>University of Lund</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="RBID">ISTEX:259_1996_Article_BF00834524.pdf</idno><date when="1996">1996</date><idno type="doi">10.1007/BF00834524</idno><idno type="wicri:Area/Main/Corpus">000230</idno><idno type="wicri:Area/Main/Curation">000230</idno><idno type="wicri:Area/Main/Exploration">000046</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvant chemotherapy</term><term>Bleomycin</term><term>Head and neck neoplasms</term><term>Indium radioisotopes</term><term>Radiation therapy</term><term>Radionuclide imaging</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="eng">Bleomycin (BLM) is used for the treatment of head and neck cancer. In order to improve the effectiveness of this chemotherapeutic drug, BLM was combined with indium-111. A complex of these agents (111In-BLMC), formed at low pH, was injected intravenously into ten head and neck cancer patients in escalating activities of 75, 175 and 375 MBq. The internally delivered dose to the tumours varied from 0.20 to 2.73 mGy at 75 MBq, from 0.33 to 2.51 mGy at 175 MBq, and from 0.87 to 31.3 mGy at the 375 MBq activity level. Uptake of radioactivity was 0.45±0.24×10−3% ID/g in primary tumours and 0.52±0.20×l0−3% ID/g in metastases (at 48 h). Tumour volumes varied from 0.51 to 49.0 cm3. The radioactivity half-lives in the tumours were 30±7 h. The activity distribution and penetration into tumour tissue were not affected by increasing the injected activity. There was a positive correlation between BLMC uptake and Ki-67/Mib activity as well as number of mitoses in tumour tissue. These data indicate that111In-BLMC has potential as a radiochemotherapeutic agent in head and neck cancer and that adjuvant Auger-electron therapy is possible using114m-In-labelled BLMC.</div></front></TEI><mods xsi:schemaLocation="http://www.loc.gov/mods/v3 file:///applis/istex/home/loadistex/home/etc/xsd/mods.xsd" version="3.4" istexId="25bef66c96e67c83def2b26e433c78e4c6b4145f"><titleInfo lang="eng"><title>Indium-111 bleomycin complex for radiochemotherapy of head and neck cancer — dosimetric and biokinetic aspects</title></titleInfo><name type="personal"><namePart type="given">Kalevi J. A.</namePart><namePart type="family">Kairemo</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Clinical Chemistry, University Central Hospital of Helsinki, Finland</affiliation><affiliation>Department of Oncology, University Central Hospital of Helsinki, Finland</affiliation></name><name type="personal"><namePart type="given">Hans A.</namePart><namePart type="family">Ramsay</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Otorhinolaryngology, University Central Hospital of Helsinki, Finland</affiliation></name><name type="personal"><namePart type="given">Magnus</namePart><namePart type="family">Tagesson</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Radiation Physics, University of Lund, Sweden</affiliation></name><name type="personal"><namePart type="given">Antti P.</namePart><namePart type="family">Jekunen</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Oncology, University Central Hospital of Helsinki, Finland</affiliation></name><name type="personal"><namePart type="given">Timo K.</namePart><namePart type="family">Paavonen</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Pathology, University of Helsinki, Finland</affiliation></name><name type="personal"><namePart type="given">Hilkka A.</namePart><namePart type="family">Jääskelä-Saari</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Otorhinolaryngology, University Central Hospital of Helsinki, Finland</affiliation></name><name type="personal"><namePart type="given">Kristian</namePart><namePart type="family">Liewendahl</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Clinical Chemistry, University Central Hospital of Helsinki, Finland</affiliation></name><name type="personal"><namePart type="given">Kaj</namePart><namePart type="family">Ljunggren</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Radiation Physics, University of Lund, Sweden</affiliation></name><name type="personal"><namePart type="given">Sauli</namePart><namePart type="family">Savolainen</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Physics, University of Helsinki, Finland</affiliation></name><name type="personal"><namePart type="given">Sven-Erik</namePart><namePart type="family">Strand</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Radiation Physics, University of Lund, Sweden</affiliation></name><typeOfResource>text</typeOfResource><genre>Original Article</genre><genre>Original Paper</genre><originInfo><publisher>Springer-Verlag, Berlin/Heidelberg</publisher><dateValid encoding="w3cdtf">2004-11-17</dateValid><copyrightDate encoding="w3cdtf">1996</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="eng">Bleomycin (BLM) is used for the treatment of head and neck cancer. In order to improve the effectiveness of this chemotherapeutic drug, BLM was combined with indium-111. A complex of these agents (111In-BLMC), formed at low pH, was injected intravenously into ten head and neck cancer patients in escalating activities of 75, 175 and 375 MBq. The internally delivered dose to the tumours varied from 0.20 to 2.73 mGy at 75 MBq, from 0.33 to 2.51 mGy at 175 MBq, and from 0.87 to 31.3 mGy at the 375 MBq activity level. Uptake of radioactivity was 0.45±0.24×10−3% ID/g in primary tumours and 0.52±0.20×l0−3% ID/g in metastases (at 48 h). Tumour volumes varied from 0.51 to 49.0 cm3. The radioactivity half-lives in the tumours were 30±7 h. The activity distribution and penetration into tumour tissue were not affected by increasing the injected activity. There was a positive correlation between BLMC uptake and Ki-67/Mib activity as well as number of mitoses in tumour tissue. These data indicate that111In-BLMC has potential as a radiochemotherapeutic agent in head and neck cancer and that adjuvant Auger-electron therapy is possible using114m-In-labelled BLMC.</abstract><subject lang="eng"><genre>Key words</genre><topic>Bleomycin</topic><topic>Indium radioisotopes</topic><topic>Radionuclide imaging</topic><topic>Radiation therapy</topic><topic>Adjuvant chemotherapy</topic><topic>Head and neck neoplasms</topic></subject><relatedItem type="series"><titleInfo type="abbreviated"><title>Eur J Nucl Med</title></titleInfo><titleInfo><title>European Journal of Nuclear Medicine</title><partNumber>Year: 1996</partNumber><partNumber>Volume: 23</partNumber><partNumber>Number: 6</partNumber></titleInfo><genre>Archive Journal</genre><originInfo><dateIssued encoding="w3cdtf">1996-06-01</dateIssued><copyrightDate encoding="w3cdtf">1996</copyrightDate></originInfo><subject usage="primary"><topic>Medicine & Public Health</topic><topic>Imaging / Radiology</topic><topic>Nuclear Medicine</topic></subject><identifier type="issn">0340-6997</identifier><identifier type="issn">Electronic: 1619-7089</identifier><identifier type="matrixNumber">259</identifier><identifier type="local">IssueArticleCount: 23</identifier><recordInfo><recordOrigin>Springer-Verlag, 1996</recordOrigin></recordInfo></relatedItem><identifier type="doi">10.1007/BF00834524</identifier><identifier type="matrixNumber">Art4</identifier><identifier type="local">BF00834524</identifier><accessCondition type="use and reproduction">MetadataGrant: OpenAccess</accessCondition><accessCondition type="use and reproduction">AbstractGrant: OpenAccess</accessCondition><accessCondition type="restriction on access">BodyPDFGrant: Restricted</accessCondition><accessCondition type="restriction on access">BodyHTMLGrant: Restricted</accessCondition><accessCondition type="restriction on access">BibliographyGrant: Restricted</accessCondition><accessCondition type="restriction on access">ESMGrant: Restricted</accessCondition><part><extent unit="pages"><start>631</start><end>638</end></extent></part><recordInfo><recordOrigin>Springer-Verlag, 1996</recordOrigin><recordIdentifier>259_1996_Article_BF00834524.pdf</recordIdentifier></recordInfo></mods></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000046 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000046 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:259_1996_Article_BF00834524.pdf
|texte= Indium-111 bleomycin complex for radiochemotherapy of head and neck cancer — dosimetric and biokinetic aspects
}}
| This area was generated with Dilib version V0.5.81. |  |